Futura Medical PLC Recording of Investor Seminar
23 Giugno 2023 - 5:30PM
RNS Non-Regulatory
TIDMFUM
Futura Medical PLC
23 June 2023
23 June 2023
Futura Medical plc
("Futura" or the "Company")
Recording of Investor Seminar
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a
pharmaceutical company developing a portfolio of innovative
products based on its proprietary, transdermal DermaSys(R) drug
delivery technology currently focused on sexual health, today
announces that a video recording of its Investor Seminar, hosted on
22 June 2023, is now available on its website.
The video recording is now available in the investor section of
the Futura website:
https://www.futuramedical.com/investor-centre/videos-and-webcasts/videos/
-ENDS-
For further information, please contact:
Futura Medical plc
James Barder, Chief Executive Officer
Angela Hildreth, Finance Director and COO
Email: investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
www.futuramedical.com
For media enquiries please contact:
Optimum Strategic Communications
Hollie Vile/ Jonathan Edwards/ Zoe Bolt
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 882 9621
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) technology. Each DermaSys(R)
formulation is separately patented and specifically tailored for
the selected indication and application, as well as being optimised
for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and
consumer healthcare markets as appropriate. Development and
commercialisation strategies are designed to maximise product
differentiation and value creation whilst minimising risk.
MED3000 is Futura's topical gel formulation that is a novel
treatment for erectile dysfunction (ED) through a unique
evaporative mode of action. Futura has conducted two Phase 3
studies using MED3000 in ED; FM57 study which enabled Futura to be
granted a CE Mark in 2021 and FM71 which enabled Futura to be
granted US marketing authorisation. Both studies demonstrated that
MED3000 presents an effective clinically proven treatment for ED
with a rapid speed of onset and a favourable benefit versus risk
profile ideally suited for an 'Over the Counter'
classification.
Eroxon(R) is FDA approved in the US, CE marked in Europe and
UKCA marked in the UK as a clinically proven topical treatment for
adult men with erectile dysfunction under the brand Eroxon(R) with
a key claim of "Helps you get an erection within 10 minutes".
Eroxon(R) is the agreed brand name in certain regions such as the
EU whereas MED3000 continues to be the internal code name used by
the Company and also in reference to countries where regulatory
approval or commercial distribution agreements have not yet been
achieved. www.eroxon.com
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange. www.futuramedical.com
.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAZZGZVKFNGFZM
(END) Dow Jones Newswires
June 23, 2023 11:30 ET (15:30 GMT)
Grafico Azioni Futura Medical (LSE:FUM)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Futura Medical (LSE:FUM)
Storico
Da Mag 2023 a Mag 2024